FDA Brief

Warning letters Drugs

FDA warning letter to

INCELL Corporation LLC

High riskIssued Dec 12, 2024Posted Jan 21, 2025Center for Biologics Evaluation and Research (CBER)

FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.

What happened

FDA inspected INCELL's San Antonio facility from September 25 to 29, 2023 and found the company makes an amniotic-fluid-derived product under contract for another firm. FDA also reviewed the product's specification sheet, promotional material and website, which showed the product is intended to treat disease or affect body function. The letter says the product is an unapproved new drug with no biologics license, is not made according to CGMP (current good manufacturing practice, the FDA rules for how drugs must be made), and that its aseptic (sterile) processes were never validated.

What FDA found

  1. The company never validated the aseptic process used to make its sterile product, for example by running media fill simulations, from February 2020 until the inspection.

    21 CFR 211.113(b)
  2. The finished-product specification has no identity test, so the company has no sound way to confirm the product is what it claims to be.

    21 CFR 211.160(b)
  3. Expiration dates were assigned to the product without stability data to support them.

    21 CFR 211.166(a)
  4. The product is an unapproved new drug and an unlicensed biological product because no biologics license application (BLA, the FDA approval for biological products) is in effect for it.

    FD&C Act 505(a), 21 U.S.C. 355(a); PHS Act 351(a)(1), 42 U.S.C. 262(a)(1)
  5. The instructions for use and certificate of analysis contain false or misleading statements about how the product is supplied and how long it lasts, making it misbranded.

    FD&C Act 502(a), 21 U.S.C. 352(a)
  6. Because manufacturing methods and controls do not meet CGMP, the product is adulterated.

    FD&C Act 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B); 21 CFR parts 210 and 211

What FDA wants

FDA asks the company to respond in writing within 15 working days describing the specific steps taken or planned to fix the violations and prevent recurrence, with supporting documentation. It also asks for the revised instructions for use and a description of what will be done about product already on the market that is still within its labeled expiry.

Who should pay attention

  • companies that contract INCELL to make or fill sterile biologic products
  • distributors and brands selling amniotic-fluid-derived products
  • clinics and physicians who buy or administer these products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk